Scientists are rapidly investigating retatrutide, a innovative medication from Eli Lilly, as a possible step in weight loss . Unlike many earlier approaches, retatrutide is a twin-action agonist targeting both GLP-1 and GIP, substances that impact appetite and blood glucose control . Preliminary